Form 4 for ROIV Roivant Sciences Ltd.
Accepted 2023-11-01 00:00:00 ET · period of report 2023-10-30 · accession 0001140361-23-050941 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2023-11-01 | 2023-10-30 | ROIV | Pulik Richard | CFO | J - Other | $8.39 | -2,360 | 277.4K | -0.8% | -$19.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2023-10-30 | J | D | 2,360 | $8.39 | 277,352 | D | — | — | (F1) Represents the sale of Common Shares pursuant to a "sell-to-cover" transaction in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of restricted stock units ("RSUs") previously granted to the reporting person. This sale was effected pursuant to a "sell to cover" policy entered into pursuant to the requirements of Rule 10b5-1 and does not represent a discretionary sale by the reporting person. |